Temsirolimus

Temsirolimus
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LC-T-8040_10mg 10 mg - -

3 - 15 business days*

80.00€
LC-T-8040_25mg 25 mg -

3 - 15 business days*

144.00€
LC-T-8040_50mg 50 mg -

3 - 15 business days*

232.00€
LC-T-8040_100mg 100 mg -

3 - 15 business days*

391.00€
LC-T-8040_200mg 200 mg -

3 - 15 business days*

594.00€
 
Solubility: Soluble in DMSO at 200 mg/mL, soluble in ethanol at 200 mg/mL, very poorly soluble in... more
Product information "Temsirolimus"
Solubility: Soluble in DMSO at 200 mg/mL, soluble in ethanol at 200 mg/mL, very poorly soluble in water, maximum solubility in plain water is estimated to be about 10-20 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility. Temsirolimus, a rapamycin (sirolimus) derivative, also known as CCI-779, is an mTOR inhibitor with anti-cancer activity. Wan, X., et al. 'CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1alpha/VEGF Signaling.' Neoplasia 8: 394-401 (2006). Antiangiogenic effects may contribute to the antitumor activity of temsirolimus observed in breast cancer. Del Bufalo, D., et al. 'Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.' Cancer Res. 66: 5549-5554 (2006). Temsirolimus showed synergistic in vivo antimyeloma effects in combination with dexamethasone in a xenograft model. Yan, H., et al. 'Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.' Cancer Res. 66: 2305-2313 (2006). In lymphoblasts from adult patients with acute lymphoblastic leukemia (ALL), cells treated with sirolimus showed an increase in apoptotic cells and a dramatic decrease in cell proliferation compared to untreated cells. Mice bearing NOD/SCID xenografts treated with temsirolimus showed a decrease in splenomegaly and in peripheral-blood blasts. On the other hand, untreated mice continued to show expansion of human ALL. Temsirolimus also down-regulated the mTOR signaling intermediate phospho-S6 in xenografted human ALL. Teachey, D.T., et al. 'The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.' Blood 107: 1149-1155 (2006). Temsirolimus is able to reverse cisplatin resistance in small cell lung cancer cell lines selected for cisplatin resistance and in cell lines derived from patients who failed cisplatin therapy. Wu, C., et al. 'Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.' Mol. Cancer 4: 25-34 (2005).
Keywords: CCI-779
Supplier: LC Laboratories
Supplier-Nr: T-8040

Properties

Application: MTOR inhibitor
MW: 1030.29 D
Formula: C56H87NO16
Purity: >99%

Database Information

CAS : 162635-04-3| Find alternatives
KEGG ID : K07203 | Find alternatives

Handling & Safety

Storage: -20°C
Shipping: +20°C (International: °C)
Signal Word: Warning
GHS Hazard Pictograms:
H Phrases: H302, H312, H332, H335, H350, H360, H373
P Phrases: P261, P264, P280, P330, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P501
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Temsirolimus"
Write a review
or to review a product.
Viewed